Harrow Health Inc

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development.The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Harrow Health Inc anticipates breakout year in 2023 post-successful Q4

Harrow Health Inc's Q4 2022 call showcased a strong performance, emphasizing strategic acquisitions and growth prospects for 2023. While challenges in expense management and pricing strategies exist, the company's leadership is focused on maximizing opportunities and delivering value to stakeholders.

Harrow Health Inc excels in Q1, poised for ophthalmic market leadership

Harrow Health Inc's Q1 2023 earnings call highlighted robust financial performance, a strategic roadmap for market leadership in ophthalmic pharmaceuticals, and positive early indicators for product success. While facing challenges in product formulations and margins, the company's focus on customer feedback and commercialization strategies presents significant growth opportunities.

Harrow Health Inc reports revenue growth driven by key products

Harrow Health Inc's Q2 2023 performance reflects positive revenue growth and a strong market position driven by VEVYE and IHEEZO.
While facing challenges with leverage ratios and net equity, the company's flexible approach and growth outlook offer opportunities for improvement.
Strengthened by recent acquisitions and stakeholder support, Harrow Health is poised for continued growth and market competitiveness.
Investors should monitor the company's financial leverage, revenue drivers, and market strategies for insights into its future performance.

Harrow Health Inc achieves record revenues, eyes market expansion

Harrow Health Inc reported strong financial performance with record revenues and growth in key metrics.
While facing challenges in certain product revenues and the compounding business, the company is optimistic about new product opportunities.
Management's confidence in the company's prospects and goals reflects a positive outlook for stakeholders.

Harrow Health Inc reports stellar Q4 results and eyes market dominance

Harrow Health Inc's Q4 2023 performance reflects robust financial growth, strategic successes, and a resilient market position, setting the stage for continued expansion.
While facing challenges such as a cyber attack impact and operational hurdles, the company's strengths in strategic focus, pricing strategy, and market opportunities position it well for future success.
With a clear vision for growth, a commitment to value creation, and a focus on market dominance in key segments, Harrow Health Inc is poised for sustained growth and profitability in the coming year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it has entered into a $100 million secured credit financing agreement with funds managed by Oaktree Capital Management, L.P. (“Oaktree”). The interest-only secured credit facility carries an interest rate equal to the three-month secured overnight financing rate (SOFR) plus 6.

Harrow Announces New $100 Million Secured Credit Facility with Oaktree

Harrow Health, Inc. (NASDAQ:HROW ) Q4 2022 Earnings Conference Call March 23, 2023 4:45 PM ET Company Participants Jamie Webb - Director, Communications and IR Mark Baum - Chief Executive Officer Andrew Boll - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Sahil Kazmi - B. Riley Securities Operator Good afternoon.

Harrow Health, Inc. (HROW) Q4 2022 Earnings Call Transcript

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced results for the fourth quarter and year ended December 31, 2022. The Company also posted its fourth quarter and year-end Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com. “2022 was truly a transformational year for Harrow,” said Mark L. Baum, CEO of Harrow.

Harrow Announces Fourth Quarter and Year-End 2022 Financial Results

NEW YORK , March 17, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Harrow Health, Inc. (NASDAQ: HROW, HROWL, HROWM) resulting from allegations that Harrow may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Harrow securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, NATIONAL TRIAL COUNSEL, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM

NEW YORK , March 13, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harrow Health, Inc. ("Harrow" or the "Company") (NASDAQ: HROW). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow Health, Inc. - HROW

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved transitional pass-through reimbursement status for IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel) 3%, which is indicated for ocular surface anesthesia.

Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3%

NEW YORK , March 11, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Harrow Health, Inc.  ("Harrow Health" or the "Company") (NASDAQ: HROW). If you suffered losses exceeding $50,000 investing in Harrow Health stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

HARROW HEALTH SHAREHOLDER ACTION REMINDER : Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options

NEW YORK , March 10, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Harrow Health, Inc. (NASDAQ: HROW, HROWL, HROWM) resulting from allegations that Harrow may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Harrow securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance, responsible for overseeing and managing all regulatory related submissions and strategy related to the Company's portfolio of new and existing products. Dr.

Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance

NEW YORK , March 2, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Harrow Health, Inc. (NASDAQ: HROW, HROWL, HROWM) resulting from allegations that Harrow may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Harrow securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Harrow Health, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2022, on Thursday, March 23, 2023, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 4:45 p.m.

Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023

LOS ANGELES, CA / ACCESSWIRE / February 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Harrow Health, Inc. ("Harrow" or "the Company") (NASDAQ:HROW) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Harrow Health, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW) investors concerning the Company's possible violations of the federal securities laws.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

BENSALEM, Pa. , Feb. 25, 2023 /PRNewswire/ -- ­Law Offices of Howard G.

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Harrow Health, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW) investors concerning the Company's possible violations of the federal securities laws.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Harrow Health, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW) investors concerning the Company's possible violations of federal securities laws. On February 22, 2023, Bonitas Research published a report alleging, among other things, that Harrow had concealed a U.S.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Harrow Health, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 22, 2023, Bonitas Research published a report alleging, among other things, that Harrow had concealed a U.S.

The Law Offices of Frank R. Cruz Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

Harrow entered an opaque market filled with middle men and dissatisfied ophthalmologists. Harrow understands their customers, solves their pain points, and has earned their trust. This is a deep moat. The company was built by founder/CEO Mark Baum from zero to a dominant position in its niche in just 9 years. Very impressive.

Buy Harrow Health: Correcting A Shortsighted View

LOS ANGELES--(BUSINESS WIRE)---- $HROW #HROW--The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Harrow Health, Inc. (NASDAQ: HROW, HROWL, HROWM) resulting from allegations that Harrow may have issued materially misleading business information to the investing public.

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation – HROW, HROWL, HROWM

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the launch of its patent-pending, next-generation compounded Atropine formulations, which are now available through Harrow's wholly owned compounding and mail order pharmacy subsidiary, ImprimisRx. In commenting on the announcement, Mark L.

Harrow Launches Next-Generation Compounded Atropine Formulations

NASHVILLE, Tenn.--( BUSINESS WIRE )--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has issued a permanent, product-specific J-code for IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia. Under the Healthcare Common Procedure Coding System (HCPCS), the IHEEZO J‑code (J2403) will become effective April 1, 2023.

Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023

NASHVILLE, Tenn.--( BUSINESS WIRE )--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the closing of its previously announced acquisition of the exclusive U.S. commercial rights to five branded ophthalmic products: ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®.

Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products

NASHVILLE, Tenn.--( BUSINESS WIRE )--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the availability, for in-office use, of Fortisite™ (compounded Tobramycin 1.5% + Vancomycin 5%) from its FDA‑registered and FDA‑inspected ImprimisRx® 503B outsourcing facility. Fortisite formulations are patent-pending high-concentration, refrigeration-stable, fortified antibiotic formulations, in solution. The availability of Fortisite for in-office use represents the first time eyecare professionals have been able to stock a fortified or high-concentration compounded antibiotic formulation for the immediate treatment of patients in need.

News for Harrow Health Inc Stock (HROW)